BARDA Archives - EverGlade

BARDA

BARDA Seeks Input on Next-Generation High-Performance Antigen Diagnostics

Download the Solicitation Overview of the RFI The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a Request for Information (RFI) titled “High Performance Antigen Diagnostics.” Through this market research effort, BARDA is seeking feedback from industry, academia, and other stakeholders to better understand the landscape of current and emerging high-performance immunoassay […]

BARDA Seeks Input on Next-Generation High-Performance Antigen Diagnostics Read More »

BARDA Issues RFP Under Project BioShield for 2-PAM Autoinjectors to Strengthen Chemical Threat Preparedness 

Download the Solicitation The Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR), has released a Request for Proposals (RFP) for 2-PAM Autoinjectors for Project BioShield. The RFP supports late-stage clinical development, regulatory approval, procurement, and delivery of pralidoxime, also known as 2-PAM, autoinjectors for the treatment of organophosphate (OP)

BARDA Issues RFP Under Project BioShield for 2-PAM Autoinjectors to Strengthen Chemical Threat Preparedness  Read More »

BARDA Releases BundiVx Solicitation to Accelerate Bundibugyo Ebola Vaccine Development

Download the Solicitation The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has officially released Request for Project Proposals (RPP) RRPV 26-13-BundiVx for the Bundibugyo Virus Outbreak Response Vaccines (BundiVx) Program. The solicitation seeks to accelerate the development of investigational vaccine candidates targeting Bundibugyo ebolavirus (BDBV), the virus responsible for

BARDA Releases BundiVx Solicitation to Accelerate Bundibugyo Ebola Vaccine Development Read More »

BARDA Seeks Input on “Protection Before Day One” Influenza Vaccines with Pandemic Coverage

Download the RFI Overview of the RFI The Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR), has released a Request for Information (RFI) titled “Protection Before Day One Vaccine: Advancing Broadly Protective Seasonal Influenza Vaccines with Pandemic Coverage.” Through this market research effort, BARDA is seeking feedback from industry, academia, and

BARDA Seeks Input on “Protection Before Day One” Influenza Vaccines with Pandemic Coverage Read More »

BARDA Seeks Input on Medical Countermeasures for Drug-Resistant Fungal Infections

Download the Solicitation The Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), has issued a Request for Information (RFI) to better understand the current development landscape for antifungal medical countermeasures. BARDA plays a central role in advancing

BARDA Seeks Input on Medical Countermeasures for Drug-Resistant Fungal Infections Read More »

BARDA Seeks Input on AI-Enabled Discovery of Broad-Spectrum Small-Molecule Filovirus Therapeutics

Download the Solicitation The Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), has issued a Request for Information (RFI) focused on AI-Enabled Discovery of Broad-Spectrum Small-Molecule Inhibitors for Filoviruses. Filoviruses, including Ebola virus (EBOV), Sudan virus

BARDA Seeks Input on AI-Enabled Discovery of Broad-Spectrum Small-Molecule Filovirus Therapeutics Read More »

BARDA-BAA-advanced-medical-countermeasures

BARDA’s Modernized BAA: A New On-Ramp for Advanced Medical Countermeasure Development

BARDA_FY23 Modernized BAA Solicitation – Amendment 7 The Biomedical Advanced Research and Development Authority (BARDA) has released its modernized Broad Agency Announcement (BAA-23-100-SOL-00004, Amendment 7), creating a flexible, multi-year pathway for industry to partner with the U.S. Government on advanced medical countermeasures (MCMs) for CBRN, pandemic influenza, and emerging infectious disease threats to the U.S.

BARDA’s Modernized BAA: A New On-Ramp for Advanced Medical Countermeasure Development Read More »

BARDA RFI Neuromuscular Junction

BARDA’s RRPV RFI on NMJ Micro-Physiological Systems for BoNT Evaluation

RRPV_RFI_BoNT-NMJ RFI Final Post Overview of Solicitation The Rapid Response Partnership Vehicle (RRPV), on behalf of the Biomedical Advanced Research and Development Authority (BARDA), has released a Request for Information (RFI) focused on neuromuscular junction (NMJ) micro-physiological systems (MPS) for botulinum neurotoxin (BoNT) applications. Managed by Advanced Technology International (ATI), this RFI seeks to assess

BARDA’s RRPV RFI on NMJ Micro-Physiological Systems for BoNT Evaluation Read More »

BARDA RRPV RAPID Solicitation Rapid Antibody Production

BARDA’s RRPV 26-10-RAPID Solicitation for Rapid Antibody Production

RRPV-26-10-RAPID The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a new Request for Project Proposals (RPP) to stand up U.S.-based rapid antibody and protein binder production platforms that can go from pathogen gene sequence to immunoassay-ready reagents within weeks instead of months. This is a targeted opportunity to position platform

BARDA’s RRPV 26-10-RAPID Solicitation for Rapid Antibody Production Read More »

BARDA RFI ARDS Prevention

BARDA RFI on Host-Directed Therapeutics for ARDS Prevention

Overview of Solicitation The Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, has released a Request for Information (RFI)/Sources Sought Notice (SSN) titled “Host Directed Therapeutics for the Prevention of Progression to ARDS.” This effort, in support of BARDA’s

BARDA RFI on Host-Directed Therapeutics for ARDS Prevention Read More »

BARDA domestic manufacturing essential medicines

BARDA Advances Domestic Manufacturing Capacity for Essential Medicines

BARDA 26-2-AM-LVP-RPP-Amendment 1 The Biomedical Advanced Research and Development Authority (BARDA), within the U.S. Department of Health and Human Services (HHS), has released a new Request for Project Proposals (RPP) aimed at strengthening the nation’s domestic pharmaceutical manufacturing base. Issued through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP Consortium), RPP 26-2-AM-LVP focuses on the commercial scale

BARDA Advances Domestic Manufacturing Capacity for Essential Medicines Read More »

SMART antiviral prize

The SMART Antiviral Prize: A $100 Million Opportunity to Advance Broad-Spectrum Antiviral Development

The Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), has launched the Small Molecule Approaches for Rapid and Robust Treatment (SMART) Antiviral Prize. This opportunity, introduced in collaboration with BARDA Accelerator Network, VITAL,  is a $100

The SMART Antiviral Prize: A $100 Million Opportunity to Advance Broad-Spectrum Antiviral Development Read More »

Scroll to Top